

Special Issue

Immuno-Oncology: Identification of Therapeutic Targets, Development of Novel Drugs and Improvement of Treatment Approaches for Cancer

Message from the Guest Editor

Dear Colleagues Recently, we witnessed an extraordinary development in cancer therapy, led by the evolving field of immuno-oncology. Compounds targeting cancer-specific mutated genes were generated, and more target molecules are currently being investigated to develop new drugs.

Immunotherapy is an evolution of targeted therapy where the immune system is targeted to improve its ability to kill cancer cells. Additionally, effective vaccines are already employed for infectious agent-related cancers and immunoprevention of cancers not related to infectious agents was observed in transgenic mice with activated oncogenes, indicating that stimulation of the immune system in healthy hosts can inhibit carcinogenesis. These strategies, are having an extraordinary success, but they can have side effects. Since these approaches are quickly taking over classic chemotherapy, perfecting immuno-oncology is essential to improve patient wellbeing. Hence, in this issue, we will discuss the most recent discoveries leading to the development of a new generation of drugs and therapeutic approaches for cancer treatment.

Guest Editor

Dr. Veronica Balatti

Research Scientist, Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA

Deadline for manuscript submissions

closed (31 July 2020)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/21918

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

jcm



About the Journal

Message from the Editorial Board

Journal of Clinical Medicine (ISSN 2077-0383) is an international, peer-reviewed, open access journal dedicated to advancing clinical and preclinical research. Our Editorial Board and staff are committed to delivering cutting-edge, timely, peer-reviewed articles spanning the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and impactful research articles, as well as reviews that are clinically significant and relevant to the full spectrum of medical disciplines. All full texts are archived in PubMed Central and indexed in SCIE (Web of Science), Scopus, PubMed, and other major databases. We invite you to submit your manuscript for publication, as well as join our community as a reviewer or reader online.

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).